Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 3/20 | 0.67 |
| ▸ | AXL | P30530 | 13/20 | 0.42 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 11/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 11/20 | 0.37 |
| ▸ | MERTK | Q12866 | 11/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907392 | 0.92 | UGCG (0.79) | UGCGAXLLCLAT1METTYRO3 | |
| SCHEMBL29907394 | 0.90 | UGCG (0.82) | UGCGAXLLCLAT1KDM4EMET | |
| SCHEMBL29907486 | 0.88 | UGCG (0.54) | UGCGAXLLCLAT1METTYRO3 | |
| SCHEMBL29907614 | 0.86 | UGCG (0.53) | UGCGLCLAT1METSCN9A | |
| SCHEMBL29907456 | 0.85 | UGCG (0.64) | UGCGAXLMETTYRO3MERTK | |
| SCHEMBL29907424 | 0.85 | UGCG (0.51) | UGCGAXLLCLAT1METTYRO3 | |
| SCHEMBL29907594 | 0.83 | UGCG (0.61) | UGCGAXLLCLAT1METTYRO3 | |
| SCHEMBL29907372 | 0.82 | UGCG (0.63) | UGCGAXLMETTYRO3MERTK | |
| SCHEMBL24464270 | 0.82 | UGCG (0.62) | UGCGAXLLCLAT1METTYRO3 | |
| SCHEMBL29907369 | 0.82 | UGCG (0.62) | UGCGLCLAT1METSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885AXL 4241/4885LCLAT1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.